AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03964103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gQ-lab daily
Description: probiotics
Study NCT03964103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: powdered skim milk, lactose
Study NCT00252421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment 15 mg/day daily for 24 month
Description: Nitroglycerin ointment 15 mg/day applied daily for 24 mth
Study NCT00252421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment daily for 24 month
Description: Placebo ointment applied daily for 24 mth
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AVL-292
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg AVL-292
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg AVL-292
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg AVL-292
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Study NCT01692184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT00189098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole-trimethoprim
Description: 18 mg/kg, two times a day
Study NCT00189098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04404179 — intervention group
Intervention type: OTHER
Intervention: COVID-19 FACILITY
Description: A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
Study NCT02399215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02399215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT02399215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02399215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04575506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Description: The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
Study NCT04575506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention program
Description: The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
Study NCT02843724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Naturopathic Care
Description: Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
Study NCT02843724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual (Conventional) Care
Description: 2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
Study NCT02268149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study NCT02268149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02268149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01172106 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: drug compliance
Description: Mothers and their caregivers will be encouraged to comply with the given medication
Study NCT01172106 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Encouragement of drug compliance
Description: Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
Study NCT01172106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Description: The experimental group will receive family psychoeducation for 12 sessions
Study NCT00716963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate (Flovent Diskus) 250 mcg
Description: Flovent Diskus 250 mcg
Study NCT00716963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide 400 mcg
Description: budesonide 400 mcg
Study NCT00716963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)
Description: gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L)
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
Study NCT00001832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous
Study NCT00001832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous
Study NCT00001832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count > 1.0 x10\^9/L x 3 days or > 5.0 x10\^9/L.
Study NCT00001832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Study NCT03497663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Family intervention
Description: Family based intervention
Study NCT03497663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual
Study NCT00450970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Satraplatin
Description: The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
Study NCT03305666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine injection
Description: A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
Study NCT03305666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine indwelling catheter
Description: Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
Study NCT02745171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
Study NCT01022021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
Study NCT01022021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
Study NCT02334930 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Study NCT02542865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified malt based food
Description: Fortified malt based food
Study NCT02677298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
Study NCT02677298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
Study NCT02677298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
Study NCT04629755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
Study NCT02360566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Video Intervention for Early Psychosis
Description: The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
Study NCT00947375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal TM
Description: First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
Study NCT00947375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Decanoate
Description: Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
Study NCT02503592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular testing
Description: Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
Study NCT01099371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: progressive resistance training
Study NCT02229058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Bound Paclitaxel
Description: 120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
Study NCT02229058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA>1.5m2,until disease progress or intolerable toxicity.
Study NCT03707353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
Study NCT04127721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT04127721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT04127721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04127721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO
Study NCT03383926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6cm suture
Description: Suture confection of the Tobacco-pouch of 6cm from the anal margin.
Study NCT01332773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery first procedure
Description: early identification of SMA to evaluate infiltration
Study NCT01332773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No artery first procedure
Description: conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
Study NCT01940185 — intervention group
Intervention type: DEVICE
Intervention: LINX device
Study NCT04127721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT04127721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT03399058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 1 5+5+5 (Control)
Description: The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
Study NCT03399058 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 2: 5+5+5 & PDH
Description: The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
Study NCT03399058 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 3: 5+5+5 & PDH lite+mHealth
Description: The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
Study NCT03267368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Care Program
Description: Pulmonary rehabilitation and smoking cessation
Study NCT00333775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
Study NCT00333775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to bevacizumab
Description: Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
Study NCT00333775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
Study NCT00364676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLI
Description: Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
Study NCT00364676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLI
Description: Patients are dosed on Day 1 of a 21-day cycle.
Study NCT01706172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 20% dextrose/ 0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
Study NCT01706172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
Study NCT01745926 — intervention group
Intervention type: DEVICE
Intervention: MECHANICAL CHEST COMPRESSION
Study NCT02110563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-MYC
Description: Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops.
Study NCT01838317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT04350281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1B
Description: Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
Study NCT04350281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
Study NCT04262700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeScan's new BGMS
Description: LifeScan new Blood Glucose Monitoring System (BGMS)
Study NCT00703014 — intervention group
Intervention type: DRUG
Intervention: Corifollitropin Alfa 150 μg
Description: In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
Study NCT00703014 — intervention group
Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 1 to 7)
Description: In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT00703014 — intervention group
Intervention type: DRUG
Intervention: Placebo for Corifollitropin Alfa
Description: In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
Study NCT00703014 — intervention group
Intervention type: DRUG
Intervention: Placebo for RecFSH/Follitropin beta
Description: In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT00703014 — intervention group
Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
Description: In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
Study NCT00703014 — intervention group
Intervention type: DRUG
Intervention: Ganirelix
Description: In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
Study NCT00703014 — intervention group
Intervention type: BIOLOGICAL
Intervention: hCG
Description: In the Base Trial P05787, when 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
Study NCT00703014 — intervention group
Intervention type: BIOLOGICAL
Intervention: Progesterone
Description: In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.